NZM2 cell line细胞株-BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

Description: NZM2 is an adherent cell line derived from a 47 year old male with melanoma metastatic to obturator lymph node.



Description Key Words: Human metastatic melanoma



Also Known As: No other names



Organism: Human (Homo sapiens)



Tissue: melanoma metastatic to obturator lymph node



Growth Properties: Adherent



Doubling Time: 70 hours



Morphology: Epithelial



Growth Medium: This cell line was established by the depositor in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS), 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%O2, 5%CO2 and 90%N2.



At CellBank Australia it has been cultured in: Alpha modified Minimum Essential Medium (MEM) supplemented with 10% Foetal Bovine Serum (FBS), 5 ug/ml Insulin, 5 ug/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), in an atmosphere of 5%CO2.



Resuscitation: Remove protective cryoflex layer around the ampoule prior to thawing. Thaw the ampoule by gently agitating in a 37°C waterbath; thawing should be rapid (around 2 minutes). A centrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.



Subculturing Procedure:



Medium Renewal: 3 times per week.



Subcultivation Ratio: 1:2 – 1:4, Seeding density 1.2 x104cells/cm2. Split subconfluent cultures(70-80%). Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 minutes.



Culture Conditions: Incubate the culture at 37°C with 5% CO2.



Cryoprotectant Medium: 10% DMSO + 90% FCS



Handling Procedure for Frozen Cells: Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability.



Additional Information:

Wild-type for BRAF, NRAS, TP53, PIK3CA, PTEN
CDKN2A/B deletion
Resistant to temozolomide;
MGMT expressed
aneuploid 1.77x diploid; chromosome number 71-78.
NZM1 and NZM2 were developed from the same patient whose malignant lymph nodes were excised 4 weeks apart.

Medium:
Growth Condition:

BioVector NTCC Inc.
www.biovector.net